Abstract
Objective
To determine whether the formation of a multidisciplinary team, pharmacist-led therapeutic
interchange, and streamlined electronic health record optimization improved biosimilar
adoption throughout Mayo Clinic.
Patients and Methods
The project focused on the use of reference products and biosimilars for 5 biologics—bevacizumab,
epoetin alfa, filgrastim, rituximab, and trastuzumab—at all Mayo Clinic locations.
Pharmaceutical wholesale purchase histories of those reference products and biosimilars
were assessed from September 1, 2020, through August 31, 2021, and compared with data
from September 1, 2019, through August 31, 2020. Formulary decisions were implemented
across 5 biologics for most ordering pathways on September 1, 2020. Pharmaceutical
purchased drug units and expenditures were tracked at 3-month intervals for conversion
to formulary-preferred contracted biosimilars.
Results
In the final postimplementation period, the absolute percentage increase of formulary-preferred
biosimilars was 69% for bevacizumab, 63% for epoetin alfa, 80% for filgrastim, 79%
for rituximab, and 72% for trastuzumab. Pharmaceutical line item savings in the 12-month
postimplementation period totaled $23.1 million across all 5 biologics.
Conclusion
Creation of a multidisciplinary team to implement formulary-preferred contracted biosimilars
led to the adoption of biosimilars throughout Mayo Clinic with considerable pharmaceutical
line item savings.
Abbreviations and Acronyms:
EHR (electronic health record), EU (European Union), FDA (US Food and Drug Administration), MCPFS (Mayo Clinic Pharmaceutical Formulary Subcommittee), SCM (supply chain management)To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Mayo Clinic ProceedingsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- National health care spending in 2019: steady growth for the fourth consecutive year.Health Aff (Millwood). 2021; 40: 14-24
- Biosimilars.https://www.healthaffairs.org/do/10.1377/hpb20131010.6409/full/Date accessed: November 3, 2021
- National trends in prescription drug expenditures and projections for 2021.Am J Health Syst Pharm. 2021; 78: 1294-1308
- Biosimilar cost savings in the United States: initial experience and future potential.Rand Health Q. 2018; 7: 3
- Considerations for adding biosimilars to formulary.Pharm Purch Prod. 2019; 16: 14-19
- Considerations in demonstrating interchangeability with a reference product: Guidance for industry.US Food & Drug Administration, May 2019 (Docket No. FDA-2017-D-0154)
- Can biosimilars help achieve the goals of US health care reform?.Cancer Manag Res. 2017; 9: 197-205
- Category Management In Purchasing : A Strategic Approach to Maximize Business Profitability.Kogan Page, 2009
- Pharmacist’s perspectives on biosimilars in oncology.(Accessed 2021)
- Recommendations on operationalizing the safe and efficient use of biosimilars in the clinical setting. NCCN Pharmacy Directors Forum White Papers.National Comprehensive Cancer Network. 2021;
- Biosimilars.https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilarsDate accessed: November 4, 2021
- The clinical implications of nocebo effects for biosimilar therapy.Front Pharmacol. 2019; 10: 1372
- Lessons from international experience with biosimilar implementation: an application of the diffusion of innovations model.Healthc Policy. 2020; 15: 16-27
- Longer-term durability of using default options in the electronic health record to increase generic prescribing rates.J Gen Intern Med. 2019; 34: 349-350
- Home dialysis in the coronavirus disease 2019 era.Adv Chronic Kidney Dis. 2020; 27: 442-446
- Clinical experience with Zarzio® in Europe: what have we learned?.Support Care Cancer. 2013; 21: 2925-2932
- Pharmacoeconomics of biosimilars: what is there to gain from them?.Curr Rheumatol Rep. 2016; 18: 50
Troein P, Newton M, Scott K, Mulligan C. White Paper: The impact of biosimilar competition in Europe. IQVIA; January 15, 2021.
- Diffusion of innovations in service organizations: systematic review and recommendations.Milbank Q. 2004; 82: 581-629
- Implementing shared decision making in the NHS.BMJ. 2010; 341: c5146
Article Info
Publication History
Published online: March 22, 2022
Footnotes
For editorial comment, see page 1044
Data Previously Presented: These data presented in part at the Hematology/Oncology Pharmacy Association Annual Conference on April 13 to 17, 2021.
Identification
Copyright
© 2022 Mayo Foundation for Medical Education and Research
